Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
In keeping with guidance from the Food and Drug Administration, the companies will not file for an emergency use authorization to distribute the vaccine until they reach another milestone: when half of the patients in their study have been observed for any safety issues for at least two months following their second dose. Pfizer expects to cross that threshold in the third week of November.
$CYDY-CytoDyn Completes Non-dilutive $15 Million Convertible Note Financing with Conversion Rate at $4.50 Per Share without Warrants
VANCOUVER, Washington, March 31, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that it completed a new non-dilutive convertible debt offering with an institutional investor, which provides $15 million of immediately available capital. The note, has a two-year maturity, bears interest at the rate of 10% per annum and is secured by all assets of the Company, excluding its intellectual property. During the first six months following the issue date, the investor may convert principal into common stock up to 1 million shares per month after which all or any part of the outstanding balance of the note is convertible into common stock.
Craig S. Eastwood, Chief Financial Officer of CytoDyn, stated, “We are pleased to close on this round of funding as we begin our journey towards commercialization. Non-dilutive capital of this nature gives us the momentum we need to forge ahead with our therapeutic indications and provides a foundation to bring leronlimab to market, which is targeted for the fourth quarter of 2020.”
About Leronlimab (PRO 140)
The FDA has granted a “Fast Track” designation to CytoDyn for two potential indications of leronlimab for deadly diseases. The first as a combination therapy with HAART for HIV-infected patients and the second is for metastatic triple-negative breast cancer. Leronlimab is an investigational humanized IgG4 mAb that blocks CCR5, a cellular receptor that is important in HIV infection, tumor metastases, and other diseases, including NASH. Leronlimab has completed nine clinical trials in over 800 people, including meeting its primary endpoints in a pivotal Phase 3 trial (leronlimab in combination with standard antiretroviral therapies in HIV-infected treatment-experienced patients).
In the setting of HIV/AIDS, leronlimab is a viral-entry inhibitor; it masks CCR5, thus protecting healthy T cells from viral infection by blocking the predominant HIV (R5) subtype from entering those cells. Leronlimab has been the subject of nine clinical trials, each of which demonstrated that leronlimab could significantly reduce or control HIV viral load in humans. The leronlimab antibody appears to be a powerful antiviral agent leading to potentially fewer side effects and less frequent dosing requirements compared with daily drug therapies currently in use.
In the setting of cancer, research has shown that CCR5 may play a role in tumor invasion, metastases, and tumor microenvironment control. Increased CCR5 expression is an indicator of disease status in several cancers. Published studies have shown that blocking CCR5 can reduce tumor metastases in laboratory and animal models of aggressive breast and prostate cancer. Leronlimab reduced human breast cancer metastasis by more than 98% in a murine xenograft model. CytoDyn is, therefore, conducting a Phase 1b/2 human clinical trial in metastatic triple-negative breast cancer and was granted Fast Track designation in May 2019.
The CCR5 receptor appears to play a central role in modulating immune cell trafficking to sites of inflammation. It may be crucial in the development of acute graft-versus-host disease (GvHD) and other inflammatory conditions. Clinical studies by others further support the concept that blocking CCR5 using a chemical inhibitor can reduce the clinical impact of acute GvHD without significantly affecting the engraftment of transplanted bone marrow stem cells. CytoDyn is currently conducting a Phase 2 clinical study with leronlimab to support further the concept that the CCR5 receptor on engrafted cells is critical for the development of acute GvHD, blocking the CCR5 receptor from recognizing specific immune signaling molecules is a viable approach to mitigating acute GvHD. The FDA has granted “orphan drug” designation to leronlimab for the prevention of GvHD.
https://markets.businessinsider.com/news/stocks/cytodyn-completes-non-dilutive-15-million-convertible-note-financing-with-conversion-rate-at-4-50-per-share-without-warrants-1029048142
$CYDY-CytoDyn Completes Non-dilutive $15 Million Convertible Note Financing with Conversion Rate at $4.50 Per Share without Warrants
VANCOUVER, Washington, March 31, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that it completed a new non-dilutive convertible debt offering with an institutional investor, which provides $15 million of immediately available capital. The note, has a two-year maturity, bears interest at the rate of 10% per annum and is secured by all assets of the Company, excluding its intellectual property. During the first six months following the issue date, the investor may convert principal into common stock up to 1 million shares per month after which all or any part of the outstanding balance of the note is convertible into common stock.
Craig S. Eastwood, Chief Financial Officer of CytoDyn, stated, “We are pleased to close on this round of funding as we begin our journey towards commercialization. Non-dilutive capital of this nature gives us the momentum we need to forge ahead with our therapeutic indications and provides a foundation to bring leronlimab to market, which is targeted for the fourth quarter of 2020.”
About Leronlimab (PRO 140)
The FDA has granted a “Fast Track” designation to CytoDyn for two potential indications of leronlimab for deadly diseases. The first as a combination therapy with HAART for HIV-infected patients and the second is for metastatic triple-negative breast cancer. Leronlimab is an investigational humanized IgG4 mAb that blocks CCR5, a cellular receptor that is important in HIV infection, tumor metastases, and other diseases, including NASH. Leronlimab has completed nine clinical trials in over 800 people, including meeting its primary endpoints in a pivotal Phase 3 trial (leronlimab in combination with standard antiretroviral therapies in HIV-infected treatment-experienced patients).
In the setting of HIV/AIDS, leronlimab is a viral-entry inhibitor; it masks CCR5, thus protecting healthy T cells from viral infection by blocking the predominant HIV (R5) subtype from entering those cells. Leronlimab has been the subject of nine clinical trials, each of which demonstrated that leronlimab could significantly reduce or control HIV viral load in humans. The leronlimab antibody appears to be a powerful antiviral agent leading to potentially fewer side effects and less frequent dosing requirements compared with daily drug therapies currently in use.
In the setting of cancer, research has shown that CCR5 may play a role in tumor invasion, metastases, and tumor microenvironment control. Increased CCR5 expression is an indicator of disease status in several cancers. Published studies have shown that blocking CCR5 can reduce tumor metastases in laboratory and animal models of aggressive breast and prostate cancer. Leronlimab reduced human breast cancer metastasis by more than 98% in a murine xenograft model. CytoDyn is, therefore, conducting a Phase 1b/2 human clinical trial in metastatic triple-negative breast cancer and was granted Fast Track designation in May 2019.
The CCR5 receptor appears to play a central role in modulating immune cell trafficking to sites of inflammation. It may be crucial in the development of acute graft-versus-host disease (GvHD) and other inflammatory conditions. Clinical studies by others further support the concept that blocking CCR5 using a chemical inhibitor can reduce the clinical impact of acute GvHD without significantly affecting the engraftment of transplanted bone marrow stem cells. CytoDyn is currently conducting a Phase 2 clinical study with leronlimab to support further the concept that the CCR5 receptor on engrafted cells is critical for the development of acute GvHD, blocking the CCR5 receptor from recognizing specific immune signaling molecules is a viable approach to mitigating acute GvHD. The FDA has granted “orphan drug” designation to leronlimab for the prevention of GvHD.
https://markets.businessinsider.com/news/stocks/cytodyn-completes-non-dilutive-15-million-convertible-note-financing-with-conversion-rate-at-4-50-per-share-without-warrants-1029048142
CytoDyn Completes Non-dilutive $15 Million Convertible Note Financing with Conversion Rate at $4.50 Per Share without Warrants
VANCOUVER, Washington, March 31, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that it completed a new non-dilutive convertible debt offering with an institutional investor, which provides $15 million of immediately available capital. The note, has a two-year maturity, bears interest at the rate of 10% per annum and is secured by all assets of the Company, excluding its intellectual property. During the first six months following the issue date, the investor may convert principal into common stock up to 1 million shares per month after which all or any part of the outstanding balance of the note is convertible into common stock.
Craig S. Eastwood, Chief Financial Officer of CytoDyn, stated, “We are pleased to close on this round of funding as we begin our journey towards commercialization. Non-dilutive capital of this nature gives us the momentum we need to forge ahead with our therapeutic indications and provides a foundation to bring leronlimab to market, which is targeted for the fourth quarter of 2020.”
About Leronlimab (PRO 140)
The FDA has granted a “Fast Track” designation to CytoDyn for two potential indications of leronlimab for deadly diseases. The first as a combination therapy with HAART for HIV-infected patients and the second is for metastatic triple-negative breast cancer. Leronlimab is an investigational humanized IgG4 mAb that blocks CCR5, a cellular receptor that is important in HIV infection, tumor metastases, and other diseases, including NASH. Leronlimab has completed nine clinical trials in over 800 people, including meeting its primary endpoints in a pivotal Phase 3 trial (leronlimab in combination with standard antiretroviral therapies in HIV-infected treatment-experienced patients).
In the setting of HIV/AIDS, leronlimab is a viral-entry inhibitor; it masks CCR5, thus protecting healthy T cells from viral infection by blocking the predominant HIV (R5) subtype from entering those cells. Leronlimab has been the subject of nine clinical trials, each of which demonstrated that leronlimab could significantly reduce or control HIV viral load in humans. The leronlimab antibody appears to be a powerful antiviral agent leading to potentially fewer side effects and less frequent dosing requirements compared with daily drug therapies currently in use.
In the setting of cancer, research has shown that CCR5 may play a role in tumor invasion, metastases, and tumor microenvironment control. Increased CCR5 expression is an indicator of disease status in several cancers. Published studies have shown that blocking CCR5 can reduce tumor metastases in laboratory and animal models of aggressive breast and prostate cancer. Leronlimab reduced human breast cancer metastasis by more than 98% in a murine xenograft model. CytoDyn is, therefore, conducting a Phase 1b/2 human clinical trial in metastatic triple-negative breast cancer and was granted Fast Track designation in May 2019.
The CCR5 receptor appears to play a central role in modulating immune cell trafficking to sites of inflammation. It may be crucial in the development of acute graft-versus-host disease (GvHD) and other inflammatory conditions. Clinical studies by others further support the concept that blocking CCR5 using a chemical inhibitor can reduce the clinical impact of acute GvHD without significantly affecting the engraftment of transplanted bone marrow stem cells. CytoDyn is currently conducting a Phase 2 clinical study with leronlimab to support further the concept that the CCR5 receptor on engrafted cells is critical for the development of acute GvHD, blocking the CCR5 receptor from recognizing specific immune signaling molecules is a viable approach to mitigating acute GvHD. The FDA has granted “orphan drug” designation to leronlimab for the prevention of GvHD.
https://markets.businessinsider.com/news/stocks/cytodyn-completes-non-dilutive-15-million-convertible-note-financing-with-conversion-rate-at-4-50-per-share-without-warrants-1029048142
The downtrend Remains very strong. Funding is still a serious issue. Expect the trend to maintain its dominance.
Anyone with 8k highlights of the Samsung financing deal?
TLTFF Basic company information.
Phase 2 study: 6 patients treated.
The company is fully financed to finish StudyII.
As per 1Q2020 Company Quarterly Newsletter.
Phase II NMIBC Clinical Study Status
In 4Q2019, Theralase filed an Investigational New Drug ("IND") application to the Food and Drug Administration ("FDA") for a pivotal Phase II NonMuscle Invasive Bladder Cancer ("NMIBC") clinical study. The IND is currently on Full Clinical Hold pending a response by Theralase, which is expected in 1Q2020.
Pending FDA acceptance of Theralase's response, Theralase will commence onboarding clincial study sites in the United States.
In the mean time, Theralase is proceeding with patient enrollment and study site onboarding in Canada.
University Health Network ("UHN")
The Phase II NMIBC clinical study ("Study II") has successfully launched in Canada, with 3 Canadian centres open for enrollment and treatment of patients.
1.(Toronto, ON) - 5 patients treated
2. McGill University Health Centre ("MUHC")(Montreal, QC) - 1 patient treated
3. London Health Sciences Centre ("LHSC") (London, ON) - 0 patient treated
To date, 6 patients have been treated.
___________________
Financial Highlights:
As per 1Q2020 Company Quarterly Newsletter.
As of November 29, 2019, Theralase has 14.98M in cash and zero debt, except for trade payables. The company is fully financed to finish StudyII.
__________________
Phase 1 (completed study) patients 5 and 6 will be hitting 24 month treatment anniversary's. Both of these patients were cancer free 18 months after single treatment.
If both patients remain cancer free after 24 months from a single treatment, the company will have unprecedented data points.
Phase 1 patients 5 and 6 were respectfully initially treated on Jan 10 and Feb 7, 2018.
https://theralase.com/pressrelease/theralase-anti-cancer-technology-used-to-treat-fifth-patient-for-bladder-cancer/
https://theralase.com/pressrelease/theralase-anti-cancer-technology-treats-sixth-patient-for-bladder-cancer/
https://theralase.com/pressrelease/patient-five-cancer-free-eighteen-months-after-single-anti-cancer-treatment/
https://theralase.com/pressrelease/patient-six-cancer-free-eighteen-months-after-single-anti-cancer-treatment/
_________________________
Theralase Technologies has a 256 per cent upside, says Mackie Research
SEPTEMBER 20, 2019 BY NICK WADDELL
https://www.cantechletter.com/2019/09/theralase-technologies-has-a-256-per-cent-upside-says-mackie-research/
In Sept stock was around .16 - .18 cents.
Currently in January it's at about .25 after an expected pullback.
______________________
Link to company PRs
https://theralase.com/press-releases/
How much money is in the bank?
How much money do they need?
Where is the money going to come from?
What is the monthly burn rate?
It is unfortunate as the quarterly reports provide limited information about IBEX and Kelly "ill-gotten gains" Whelan's holdings.
I want to know how many actual shares of the OS she controlled at the time of her takeover of BIEL. Why is this question so hard for her to address. I've asked her privately and publically, the only response is "I can do whatever I want. If you don't like how the family business is run, sell and go away."
__________________________
Thanks for your posts.
May 20, 2016 anymore current information?
__AVXL RECEIVES ORPHAN DRUG DESIGNATION FOR RETT SYNDROME!!!!!!!
Quote:
NEW YORK, NY – May 20, 2016 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer’s disease, other central nervous system (CNS) diseases, pain and various types of cancer, today reports the U.S. Food and Drug Administration’s (FDA) Office of Orphan Product Development (OOPD) has granted Orphan Drug Designation (ODD) to ANAVEX 2-73 for the treatment of Rett syndrome.
© 2020 InvestorsHub.com, Inc. ______________________
Looks like death spiral toxic financing.
Just another version of this.
Mom and Pop getting nailed.
Oh, and there are about 40 billion more shares on there way as toxic convertible promissory notes are scheduled to hit the OS. AND, Kelly "ill-gotten gains" Whelan stands to profit from most of those notes.
___________________
Good Copy ... smells like a pump to dump. That's my current assessment.
NO LINKS JUST TALK.
EXPECT MORE OF THE SAME.
Yes, Sir. Just saw this Top 10 Active Stock Market Forums
Links? 22billionSS Yikes.. How much Debt?
I'm lookin nothing to grab just yet.
Talk is cheap ya'll.
NTS- CONTINUING DOWNTREND.
Unable to maintain stability.
Further decrease in PPS underway.
Monthly Charts shows further capital flight.
3 month monthly shows very horrific support.
Someone sold 23 bucks of stock.. 100 shares
They want your shares.
WOW.. Thats some good info!!
I know that's right. They said in a PR recently that patient enrollment will be going faster now that more hospitals are enrolled!
Exciting times for sure!!
TLTFF long.
This is one aggressive downtrend. wow.
3 month, 6 month, 1 year charts, all downtrending in progress.
Catching falling knifes is dangerous.
There is no stability in the chart.
More pain to come here.
The market is speaking in price action, it is saying...
sell sell sell
The market is speaking, listen to the market.
Ph 2 is going well. The science is solid.
Another company have success with the science just underscores that PDT treatments are the next huge thing in cancer treatments.
Theralase Researchers Receive Recognition for Recent Scientific Publications November 27, 2019
The recognition from three scientific institutes emphasizes the strong science-based technology that the Company possesses, verifying that Theralase’s Ruthenium-based PDCs are leading the pack in terms of performance of Photo Dynamic Therapy (“PDT”) metal based PDCs to become the next viable option for treating various cancers, suggesting a major change in the way various cancers are treated in the future.
The review article, titled “Metal-Based photosensitizers for photodynamic therapy – the future of multimodal oncology?”, is available online at www.sciencedirect.com and will be published in a special issue of Current Opinion in Chemical Biology entitled Next Generation Therapeutics, Volume 56, June 2020. The article verifies that the Company’s lead PDC TLD-1433 has strong scientific support, is highly advanced in clinical studies and may become the next “gold standard” cancer treatment.
https://theralase.com/pressrelease/theralase-researchers-receive-recognition-for-recent-scientific-publications/
You are completely wrong.
https://clinicaltrials.gov/ct2/show/NCT03945162?term=1433&draw=2&rank=2
Theralase Researchers Receive Recognition for Recent Scientific Publications November 27, 2019
The recognition from three scientific institutes emphasizes the strong science-based technology that the Company possesses, verifying that Theralase’s Ruthenium-based PDCs are leading the pack in terms of performance of Photo Dynamic Therapy (“PDT”) metal based PDCs to become the next viable option for treating various cancers, suggesting a major change in the way various cancers are treated in the future.
The review article, titled “Metal-Based photosensitizers for photodynamic therapy – the future of multimodal oncology?”, is available online at www.sciencedirect.com and will be published in a special issue of Current Opinion in Chemical Biology entitled Next Generation Therapeutics, Volume 56, June 2020. The article verifies that the Company’s lead PDC TLD-1433 has strong scientific support, is highly advanced in clinical studies and may become the next “gold standard” cancer treatment.
https://theralase.com/pressrelease/theralase-researchers-receive-recognition-for-recent-scientific-publications/
Toronto company-TLTFF successfully sues anonymous internet trolls
https://www.blogto.com/city/2020/01/toronto-company-just-successfully-sued-some-anonymous-internet-trolls-over-100k/
Twelve internet forum users who were found to have anonymously (or so they thought) posted defamatory comments about the owners of a Toronto-based biotechnology firm were just ordered by an Ontario Superior Court judge to pay up to $75,000 — each — in damages.
There's a hitch, however, in that only two of said online trolls have actually been identified by name.
Justice Frederick Myers released his precedent-setting judgment on Monday after hearing the case of Theralase Technologies Inc. vs. Charles Lanter, Michael Borovec and "John Doe" numbers 1 through 10.
"If people want to make hurtful statements about others and then try to hide from the responsibility to prove the truth or other justification for doing so... their cowardice is reprehensible," wrote Myers in the summary of his ruling.
"In my view, they should bear costs on a substantial indemnity basis."
The case stems from a series of false and inflammatory statements posted about Theralase founder Roger Dumoulin-White and his wife, Kristina Hachey, in a forum on the website Stockhouse.com during 2014 and 2015.
Stockhouse, a resource for small cap investors, maintains forum channels dedicated to individual companies for members to discuss trades and provide one another with advice.
All 12 defendants are alleged to have written things in Stockhouse's Theralase-specific forum that could have reasonably damaged the company's ability to make money.
"Generalizing for introductory purposes, the postings assert that Theralase management are untruthful and unprofessional, the corporation is operating unlawfully and improperly from the investors’ perspectives, and the personal plaintiffs are unprofessional, incompetent managers who have committed criminal acts," writes Myers.
"Ms. Hachey is also the subject of at least one misogynistic post that is particularly disgusting."
That post, written by someone with the screen name NASTYNASTA, asks how much it would cost to have sex with Hachey, who is also Theralase's CEO, suggesting that $200 USD would be an appropriate figure
"As the pseudonym suggests, this poster was deliberately disgusting and hurtful... Ms. Hachey testifies to having felt threatened and demeaned," wrote Myers in his ruling, ordering NASTYNASTA to pay a total of $35,000 in aggravated, general and punitive damages.
Stockhouse provided Dumoulin-White and Hachey with email addresses for all but one of the forum members who had posted malicious remarks about them. Lawyers for Theralase sent libel notices and requests for identification to all of these email addresses, as well as to the inboxes of forum accounts that were still active.
Only Lanter complied with the request, though another (Borovic) was identified by Theralese as a former employee.
With the exception of Lanter, all of the defendants were "duly noted in default," meaning that they legally admitted to the allegations by failing to contest them.
As a group, the defendants must jointly pay $55,000 in legal fees, but their individual financial penalties vary widely based on the severity of their posts
Borovec, who called Dumoulin-White and Hachey liars, sociopaths, scum, frauds and, in the case of the latter, a "bipolar pot-head," was ordered to pay $15,000 to Theralase and $40,000 to each of the plaintiffs for libel, aggravated and general damages.
"Mr. Borovec is a disgruntled former employee. His posts lay bare his express malice against the plaintiffs," wrote Myers. "His threats and the particularly scurrilous nature of his posts have caused extra humiliation and suffering by the human plaintiffs."
Collecting this money from Borovec will likely prove less difficult than collecting from those who are only known by pseudonyms and email addresses.
Nonetheless, Myers has deemed the suit legitimate in light of the fact that all defaulting defendants were "served at an email address provided by him or her to Stockhouse.com or through their website private messaging accounts on the Stockhouse.com site."
"How the plaintiffs will go about amending the title of proceedings for enforcement purposes once they identify one or more of the defendants is not before me," noted Myers
Toronto company-TLTFF successfully sues anonymous internet trolls
https://www.blogto.com/city/2020/01/toronto-company-just-successfully-sued-some-anonymous-internet-trolls-over-100k/
Twelve internet forum users who were found to have anonymously (or so they thought) posted defamatory comments about the owners of a Toronto-based biotechnology firm were just ordered by an Ontario Superior Court judge to pay up to $75,000 — each — in damages.
There's a hitch, however, in that only two of said online trolls have actually been identified by name.
Justice Frederick Myers released his precedent-setting judgment on Monday after hearing the case of Theralase Technologies Inc. vs. Charles Lanter, Michael Borovec and "John Doe" numbers 1 through 10.
"If people want to make hurtful statements about others and then try to hide from the responsibility to prove the truth or other justification for doing so... their cowardice is reprehensible," wrote Myers in the summary of his ruling.
"In my view, they should bear costs on a substantial indemnity basis."
The case stems from a series of false and inflammatory statements posted about Theralase founder Roger Dumoulin-White and his wife, Kristina Hachey, in a forum on the website Stockhouse.com during 2014 and 2015.
Stockhouse, a resource for small cap investors, maintains forum channels dedicated to individual companies for members to discuss trades and provide one another with advice.
All 12 defendants are alleged to have written things in Stockhouse's Theralase-specific forum that could have reasonably damaged the company's ability to make money.
"Generalizing for introductory purposes, the postings assert that Theralase management are untruthful and unprofessional, the corporation is operating unlawfully and improperly from the investors’ perspectives, and the personal plaintiffs are unprofessional, incompetent managers who have committed criminal acts," writes Myers.
"Ms. Hachey is also the subject of at least one misogynistic post that is particularly disgusting."
That post, written by someone with the screen name NASTYNASTA, asks how much it would cost to have sex with Hachey, who is also Theralase's CEO, suggesting that $200 USD would be an appropriate figure
"As the pseudonym suggests, this poster was deliberately disgusting and hurtful... Ms. Hachey testifies to having felt threatened and demeaned," wrote Myers in his ruling, ordering NASTYNASTA to pay a total of $35,000 in aggravated, general and punitive damages.
Stockhouse provided Dumoulin-White and Hachey with email addresses for all but one of the forum members who had posted malicious remarks about them. Lawyers for Theralase sent libel notices and requests for identification to all of these email addresses, as well as to the inboxes of forum accounts that were still active.
Only Lanter complied with the request, though another (Borovic) was identified by Theralese as a former employee.
With the exception of Lanter, all of the defendants were "duly noted in default," meaning that they legally admitted to the allegations by failing to contest them.
As a group, the defendants must jointly pay $55,000 in legal fees, but their individual financial penalties vary widely based on the severity of their posts
Borovec, who called Dumoulin-White and Hachey liars, sociopaths, scum, frauds and, in the case of the latter, a "bipolar pot-head," was ordered to pay $15,000 to Theralase and $40,000 to each of the plaintiffs for libel, aggravated and general damages.
"Mr. Borovec is a disgruntled former employee. His posts lay bare his express malice against the plaintiffs," wrote Myers. "His threats and the particularly scurrilous nature of his posts have caused extra humiliation and suffering by the human plaintiffs."
Collecting this money from Borovec will likely prove less difficult than collecting from those who are only known by pseudonyms and email addresses.
Nonetheless, Myers has deemed the suit legitimate in light of the fact that all defaulting defendants were "served at an email address provided by him or her to Stockhouse.com or through their website private messaging accounts on the Stockhouse.com site."
"How the plaintiffs will go about amending the title of proceedings for enforcement purposes once they identify one or more of the defendants is not before me," noted Myers
https://www.blogto.com/city/2020/01/toronto-company-just-successfully-sued-some-anonymous-internet-trolls-over-100k/
$TLTFF-Phase 2 study: 6 patients treated.
The company is fully financed to finish StudyII.
As per 1Q2020 Company Quarterly Newsletter.
Phase II NMIBC Clinical Study Status
In 4Q2019, Theralase filed an Investigational New Drug ("IND") application to the Food and Drug Administration ("FDA") for a pivotal Phase II NonMuscle Invasive Bladder Cancer ("NMIBC") clinical study. The IND is currently on Full Clinical Hold pending a response by Theralase, which is expected in 1Q2020.
Pending FDA acceptance of Theralase's response, Theralase will commence onboarding clincial study sites in the United States.
In the mean time, Theralase is proceeding with patient enrollment and study site onboarding in Canada.
University Health Network ("UHN")
The Phase II NMIBC clinical study ("Study II") has successfully launched in Canada, with 3 Canadian centres open for enrollment and treatment of patients.
1.(Toronto, ON) - 5 patients treated
2. McGill University Health Centre ("MUHC")(Montreal, QC) - 1 patient treated
3. London Health Sciences Centre ("LHSC") (London, ON) - 0 patient treated
To date, 6 patients have been treated.
___________________
Financial Highlights:
As per 1Q2020 Company Quarterly Newsletter.
As of November 29, 2019, Theralase has 14.98M in cash and zero debt, except for trade payables. The company is fully financed to finish StudyII.
__________________
Phase 1 (completed study) both patients 5 and 6 will be hitting 24 month treatment anniversary's. Both of these patients were cancer free 18 months after single treatment.
If both patients remain cancer free after 24 months from a single treatment, the company will have unprecedented data points.
Phase 1 patients 5 and 6 were respectfully initially treated on Jan 10 and Feb 7, 2018.
https://theralase.com/pressrelease/theralase-anti-cancer-technology-used-to-treat-fifth-patient-for-bladder-cancer/
https://theralase.com/pressrelease/theralase-anti-cancer-technology-treats-sixth-patient-for-bladder-cancer/
https://theralase.com/pressrelease/patient-five-cancer-free-eighteen-months-after-single-anti-cancer-treatment/
https://theralase.com/pressrelease/patient-six-cancer-free-eighteen-months-after-single-anti-cancer-treatment/
_________________________
Theralase Further Validates Anti-Cancer Memory Response
November 12, 2014
In research conducted at UHN in March 2012, mice were injected with 350,000 colon cancer cells (mouse cell line CT26.CL25) to produce cancerous tumours that were allowed to grow to approximately five millimeters in size. These tumours were treated with an injection of one of Theralase’s lead PDCs and then illuminated by Near Infrared (“NIR”) light to activate the PDC. The vast majority of tumours were completely destroyed. These mice were closely monitored for 20 months post treatment, until November 2013, where they remained cancer free.
In research conducted at UHN in May 2014, mice were again treated according to the March 2012 protocol and the mice who received the initial, successful Photo Dynamic Therapy (“PDT”) were re-injected with an equal number of colon cancer cells, 10 to 23 days later. With no further treatment intervention, 60% of the mice did not demonstrate tumour regrowth, while 40% had a small tumour regrowth, which was quickly destroyed. This raises the possibility of a short-term immune-mediated “memory response” that destroys cancer cells, with no further intervention.
In the latest research completed in November 2014, mice were again treated according to the March 2012 protocol and all of the mice who received the initial Photo Dynamic Therapy (“PDT”) were successfully treated and remained cancer free. These mice were then re-injected with an equal number of colon cancer cells 20 days later and with no further treatment intervention none of these mice demonstrated tumour regrowth. This confirms and further validates an ability to destroy the primary tumour and strongly suggests protection of the animal via the immune system leading to a short-term immune-mediated “memory response”.
The initial results in March 2012 and May 2014, have now been further validated by Theralase and UHN scientists this month, with a new set of animals confirming the immune-mediated “memory response”. This anti-cancer memory response suggests a major breakthrough in cancer research and may provide substantial treatment benefit and survival advantage to cancer patients. Technology that is able to rapidly and effectively destroy “patient-specific” cancer cells, prevent their recurrence and provide long lasting protection against local and distant metastasis, offers immense clinical benefit to cancer patients and the facilities that treat their disease.
https://theralase.com/pressrelease/theralase-validates-anti-cancer-memory-response/
The clinical study of mice included...
Survival of mice up to 20 months (50 human years) after one Theralase PDT treatment.
If Phase 1 patients went 2.5 years being cancer free, that would only capture 5% of the time the mice were cancer free.
_________________________
Theralase Technologies has a 256 per cent upside, says Mackie Research
SEPTEMBER 20, 2019 BY NICK WADDELL
https://www.cantechletter.com/2019/09/theralase-technologies-has-a-256-per-cent-upside-says-mackie-research/
In Sept stock was around .16 - .18 cents.
Currently in January it's at about .25 after an expected pullback.
______________________
Link to company PRs
https://theralase.com/press-releases/
______________________
Theralase Wins Precedent-Setting Lawsuit Against Anonymous Individuals for Posting Defamatory Comments Online
Thursday, January 16, 2020 4:15 PM
https://www.accesswire.com/573350/Theralase-Wins-Precedent-Setting-Lawsuit-Against-Anonymous-Individuals-for-Posting-Defamatory-Comments-Online
____________________
Potential upcoming PR's
- announcement(s) of new ph1 trial(s) for new indication(s) (additional cancer types)
- FDA approval of US-based test sites for ph2 NMIBC trials
- additional results from ph 1b trials (over longer time periods)
- JV or other interest from big pharma
- more Canada-based ph2 test sites
- more enrolled patients
$TLTFF-Phase 2 study: 6 patients treated.
The company is fully financed to finish StudyII.
As per 1Q2020 Company Quarterly Newsletter.
Phase II NMIBC Clinical Study Status
In 4Q2019, Theralase filed an Investigational New Drug ("IND") application to the Food and Drug Administration ("FDA") for a pivotal Phase II NonMuscle Invasive Bladder Cancer ("NMIBC") clinical study. The IND is currently on Full Clinical Hold pending a response by Theralase, which is expected in 1Q2020.
Pending FDA acceptance of Theralase's response, Theralase will commence onboarding clincial study sites in the United States.
In the mean time, Theralase is proceeding with patient enrollment and study site onboarding in Canada.
University Health Network ("UHN")
The Phase II NMIBC clinical study ("Study II") has successfully launched in Canada, with 3 Canadian centres open for enrollment and treatment of patients.
1.(Toronto, ON) - 5 patients treated
2. McGill University Health Centre ("MUHC")(Montreal, QC) - 1 patient treated
3. London Health Sciences Centre ("LHSC") (London, ON) - 0 patient treated
To date, 6 patients have been treated.
___________________
Financial Highlights:
As per 1Q2020 Company Quarterly Newsletter.
As of November 29, 2019, Theralase has 14.98M in cash and zero debt, except for trade payables. The company is fully financed to finish StudyII.
__________________
Phase 1 (completed study) both patients 5 and 6 will be hitting 24 month treatment anniversary's. Both of these patients were cancer free 18 months after single treatment.
If both patients remain cancer free after 24 months from a single treatment, the company will have unprecedented data points.
Phase 1 patients 5 and 6 were respectfully initially treated on Jan 10 and Feb 7, 2018.
https://theralase.com/pressrelease/theralase-anti-cancer-technology-used-to-treat-fifth-patient-for-bladder-cancer/
https://theralase.com/pressrelease/theralase-anti-cancer-technology-treats-sixth-patient-for-bladder-cancer/
https://theralase.com/pressrelease/patient-five-cancer-free-eighteen-months-after-single-anti-cancer-treatment/
https://theralase.com/pressrelease/patient-six-cancer-free-eighteen-months-after-single-anti-cancer-treatment/
_________________________
Theralase Further Validates Anti-Cancer Memory Response
November 12, 2014
In research conducted at UHN in March 2012, mice were injected with 350,000 colon cancer cells (mouse cell line CT26.CL25) to produce cancerous tumours that were allowed to grow to approximately five millimeters in size. These tumours were treated with an injection of one of Theralase’s lead PDCs and then illuminated by Near Infrared (“NIR”) light to activate the PDC. The vast majority of tumours were completely destroyed. These mice were closely monitored for 20 months post treatment, until November 2013, where they remained cancer free.
In research conducted at UHN in May 2014, mice were again treated according to the March 2012 protocol and the mice who received the initial, successful Photo Dynamic Therapy (“PDT”) were re-injected with an equal number of colon cancer cells, 10 to 23 days later. With no further treatment intervention, 60% of the mice did not demonstrate tumour regrowth, while 40% had a small tumour regrowth, which was quickly destroyed. This raises the possibility of a short-term immune-mediated “memory response” that destroys cancer cells, with no further intervention.
In the latest research completed in November 2014, mice were again treated according to the March 2012 protocol and all of the mice who received the initial Photo Dynamic Therapy (“PDT”) were successfully treated and remained cancer free. These mice were then re-injected with an equal number of colon cancer cells 20 days later and with no further treatment intervention none of these mice demonstrated tumour regrowth. This confirms and further validates an ability to destroy the primary tumour and strongly suggests protection of the animal via the immune system leading to a short-term immune-mediated “memory response”.
The initial results in March 2012 and May 2014, have now been further validated by Theralase and UHN scientists this month, with a new set of animals confirming the immune-mediated “memory response”. This anti-cancer memory response suggests a major breakthrough in cancer research and may provide substantial treatment benefit and survival advantage to cancer patients. Technology that is able to rapidly and effectively destroy “patient-specific” cancer cells, prevent their recurrence and provide long lasting protection against local and distant metastasis, offers immense clinical benefit to cancer patients and the facilities that treat their disease.
https://theralase.com/pressrelease/theralase-validates-anti-cancer-memory-response/
The clinical study of mice included...
Survival of mice up to 20 months (50 human years) after one Theralase PDT treatment.
If Phase 1 patients went 2.5 years being cancer free, that would only capture 5% of the time the mice were cancer free.
_________________________
Theralase Technologies has a 256 per cent upside, says Mackie Research
SEPTEMBER 20, 2019 BY NICK WADDELL
https://www.cantechletter.com/2019/09/theralase-technologies-has-a-256-per-cent-upside-says-mackie-research/
In Sept stock was around .16 - .18 cents.
Currently in January it's at about .25 after an expected pullback.
______________________
Link to company PRs
https://theralase.com/press-releases/
______________________
Theralase Wins Precedent-Setting Lawsuit Against Anonymous Individuals for Posting Defamatory Comments Online
Thursday, January 16, 2020 4:15 PM
https://www.accesswire.com/573350/Theralase-Wins-Precedent-Setting-Lawsuit-Against-Anonymous-Individuals-for-Posting-Defamatory-Comments-Online
____________________
Potential upcoming PR's
- announcement(s) of new ph1 trial(s) for new indication(s) (additional cancer types)
- FDA approval of US-based test sites for ph2 NMIBC trials
- additional results from ph 1b trials (over longer time periods)
- JV or other interest from big pharma
- more Canada-based ph2 test sites
- more enrolled patients
Theralase Further Validates Anti-Cancer Memory Response
November 12, 2014
In research conducted at UHN in March 2012, mice were injected with 350,000 colon cancer cells (mouse cell line CT26.CL25) to produce cancerous tumours that were allowed to grow to approximately five millimeters in size. These tumours were treated with an injection of one of Theralase’s lead PDCs and then illuminated by Near Infrared (“NIR”) light to activate the PDC. The vast majority of tumours were completely destroyed. These mice were closely monitored for 20 months post treatment, until November 2013, where they remained cancer free.
In research conducted at UHN in May 2014, mice were again treated according to the March 2012 protocol and the mice who received the initial, successful Photo Dynamic Therapy (“PDT”) were re-injected with an equal number of colon cancer cells, 10 to 23 days later. With no further treatment intervention, 60% of the mice did not demonstrate tumour regrowth, while 40% had a small tumour regrowth, which was quickly destroyed. This raises the possibility of a short-term immune-mediated “memory response” that destroys cancer cells, with no further intervention.
In the latest research completed in November 2014, mice were again treated according to the March 2012 protocol and all of the mice who received the initial Photo Dynamic Therapy (“PDT”) were successfully treated and remained cancer free. These mice were then re-injected with an equal number of colon cancer cells 20 days later and with no further treatment intervention none of these mice demonstrated tumour regrowth. This confirms and further validates an ability to destroy the primary tumour and strongly suggests protection of the animal via the immune system leading to a short-term immune-mediated “memory response”.
The initial results in March 2012 and May 2014, have now been further validated by Theralase and UHN scientists this month, with a new set of animals confirming the immune-mediated “memory response”. This anti-cancer memory response suggests a major breakthrough in cancer research and may provide substantial treatment benefit and survival advantage to cancer patients. Technology that is able to rapidly and effectively destroy “patient-specific” cancer cells, prevent their recurrence and provide long lasting protection against local and distant metastasis, offers immense clinical benefit to cancer patients and the facilities that treat their disease.
https://theralase.com/pressrelease/theralase-validates-anti-cancer-memory-response/
$TLTFF-Phase 2 study: 6 patients treated.
The company is fully financed to finish StudyII.
As per 1Q2020 Company Quarterly Newsletter.
Phase II NMIBC Clinical Study Status
In 4Q2019, Theralase filed an Investigational New Drug ("IND") application to the Food and Drug Administration ("FDA") for a pivotal Phase II NonMuscle Invasive Bladder Cancer ("NMIBC") clinical study. The IND is currently on Full Clinical Hold pending a response by Theralase, which is expected in 1Q2020.
Pending FDA acceptance of Theralase's response, Theralase will commence onboarding clincial study sites in the United States.
In the mean time, Theralase is proceeding with patient enrollment and study site onboarding in Canada.
University Health Network ("UHN")
The Phase II NMIBC clinical study ("Study II") has successfully launched in Canada, with 3 Canadian centres open for enrollment and treatment of patients.
1.(Toronto, ON) - 5 patients treated
2. McGill University Health Centre ("MUHC")(Montreal, QC) - 1 patient treated
3. London Health Sciences Centre ("LHSC") (London, ON) - 0 patient treated
To date, 6 patients have been treated.
___________________
Financial Highlights:
As per 1Q2020 Company Quarterly Newsletter.
As of November 29, 2019, Theralase has 14.98M in cash and zero debt, except for trade payables. The company is fully financed to finish StudyII.
__________________
Phase 1 (completed study) patients 5 and 6 will be hitting 24 month treatment anniversary's. Both of these patients were cancer free 18 months after single treatment.
If both patients remain cancer free after 24 months from a single treatment, the company will have unprecedented data points.
Phase 1 patients 5 and 6 were respectfully initially treated on Jan 10 and Feb 7, 2018.
https://theralase.com/pressrelease/theralase-anti-cancer-technology-used-to-treat-fifth-patient-for-bladder-cancer/
https://theralase.com/pressrelease/theralase-anti-cancer-technology-treats-sixth-patient-for-bladder-cancer/
https://theralase.com/pressrelease/patient-five-cancer-free-eighteen-months-after-single-anti-cancer-treatment/
https://theralase.com/pressrelease/patient-six-cancer-free-eighteen-months-after-single-anti-cancer-treatment/
_________________________
Theralase Technologies has a 256 per cent upside, says Mackie Research
SEPTEMBER 20, 2019 BY NICK WADDELL
https://www.cantechletter.com/2019/09/theralase-technologies-has-a-256-per-cent-upside-says-mackie-research/
In Sept stock was around .16 - .18 cents.
Currently in January it's at about .25 after an expected pullback.
______________________
Link to company PRs
https://theralase.com/press-releases/
$TLTFF-Shawn Shirazi, Chief Executive Officer , Theralase Technologies Inc.
Theralase Technologies Inc.
Filmed on: Dec 18, 2019
https://theralase.com/
Shawn Shirazi, Chief Executive Officer , Theralase Technologies Inc.
Theralase Technologies Inc.
Filmed on: Dec 18, 2019
https://theralase.com/
This is whats on my mind.
The clinical study of mice included...
Survival of mice up to 20 months (50 human years) after one Theralase PDT treatment.
If Phase 1 patients went 2.5 years being cancer free, that would only capture 5% of the time the mice were cancer free.
(I got that info from the intro pages of this site. It's by the mouse pictures.)
[b]$TLTFF-Phase 2 study: 6 patients treated.
The company is fully financed to finish StudyII.
As per 1Q2020 Company Quarterly Newsletter.
Phase II NMIBC Clinical Study Status
In 4Q2019, Theralase filed an Investigational New Drug ("IND") application to the Food and Drug Administration ("FDA") for a pivotal Phase II NonMuscle Invasive Bladder Cancer ("NMIBC") clinical study. The IND is currently on Full Clinical Hold pending a response by Theralase, which is expected in 1Q2020.
Pending FDA acceptance of Theralase's response, Theralase will commence onboarding clincial study sites in the United States.
In the mean time, Theralase is proceeding with patient enrollment and study site onboarding in Canada.
University Health Network ("UHN")
The Phase II NMIBC clinical study ("Study II") has successfully launched in Canada, with 3 Canadian centres open for enrollment and treatment of patients.
1.(Toronto, ON) - 5 patients treated
2. McGill University Health Centre ("MUHC")(Montreal, QC) - 1 patient treated
3. London Health Sciences Centre ("LHSC") (London, ON) - 0 patient treated
To date, 6 patients have been treated.
___________________
Financial Highlights:
As per 1Q2020 Company Quarterly Newsletter.
As of November 29, 2019, Theralase has 14.98M in cash and zero debt, except for trade payables. The company is fully financed to finish StudyII.
__________________
Phase 1 (completed study) patients 5 and 6 will be hitting 24 month treatment anniversary's. Both of these patients were cancer free 18 months after single treatment.
If both patients remain cancer free after 24 months from a single treatment, the company will have unprecedented data points.
Phase 1 patients 5 and 6 were respectfully initially treated on Jan 10 and Feb 7, 2018.
https://theralase.com/pressrelease/theralase-anti-cancer-technology-used-to-treat-fifth-patient-for-bladder-cancer/
https://theralase.com/pressrelease/theralase-anti-cancer-technology-treats-sixth-patient-for-bladder-cancer/
https://theralase.com/pressrelease/patient-five-cancer-free-eighteen-months-after-single-anti-cancer-treatment/
https://theralase.com/pressrelease/patient-six-cancer-free-eighteen-months-after-single-anti-cancer-treatment/
_________________________
Theralase Technologies has a 256 per cent upside, says Mackie Research
SEPTEMBER 20, 2019 BY NICK WADDELL
https://www.cantechletter.com/2019/09/theralase-technologies-has-a-256-per-cent-upside-says-mackie-research/
In Sept stock was around .16 - .18 cents.
Currently in January it's at about .25 after an expected pullback from a recent high of .295 in 2020.
______________________
Link to company PRs
https://theralase.com/press-releases/
______________________
Potential upcoming PRs
- announcement(s) of new ph1 trial(s) for new indication(s) (additional cancer types)
- FDA approval of US-based test sites for ph2 NMIBC trials
- additional results from ph 1b trials (over longer time periods)
- JV or other interest from big pharma
- more Canada-based ph2 test sites
- more enrolled patients
[b]$TLTFF-Phase 2 study: 6 patients treated.
The company is fully financed to finish StudyII.
As per 1Q2020 Company Quarterly Newsletter.
Phase II NMIBC Clinical Study Status
In 4Q2019, Theralase filed an Investigational New Drug ("IND") application to the Food and Drug Administration ("FDA") for a pivotal Phase II NonMuscle Invasive Bladder Cancer ("NMIBC") clinical study. The IND is currently on Full Clinical Hold pending a response by Theralase, which is expected in 1Q2020.
Pending FDA acceptance of Theralase's response, Theralase will commence onboarding clincial study sites in the United States.
In the mean time, Theralase is proceeding with patient enrollment and study site onboarding in Canada.
University Health Network ("UHN")
The Phase II NMIBC clinical study ("Study II") has successfully launched in Canada, with 3 Canadian centres open for enrollment and treatment of patients.
1.(Toronto, ON) - 5 patients treated
2. McGill University Health Centre ("MUHC")(Montreal, QC) - 1 patient treated
3. London Health Sciences Centre ("LHSC") (London, ON) - 0 patient treated
To date, 6 patients have been treated.
___________________
Financial Highlights:
As per 1Q2020 Company Quarterly Newsletter.
As of November 29, 2019, Theralase has 14.98M in cash and zero debt, except for trade payables. The company is fully financed to finish StudyII.
__________________
Phase 1 (completed study) patients 5 and 6 will be hitting 24 month treatment anniversary's. Both of these patients were cancer free 18 months after single treatment.
If both patients remain cancer free after 24 months from a single treatment, the company will have unprecedented data points.
Phase 1 patients 5 and 6 were respectfully initially treated on Jan 10 and Feb 7, 2018.
https://theralase.com/pressrelease/theralase-anti-cancer-technology-used-to-treat-fifth-patient-for-bladder-cancer/
https://theralase.com/pressrelease/theralase-anti-cancer-technology-treats-sixth-patient-for-bladder-cancer/
https://theralase.com/pressrelease/patient-five-cancer-free-eighteen-months-after-single-anti-cancer-treatment/
https://theralase.com/pressrelease/patient-six-cancer-free-eighteen-months-after-single-anti-cancer-treatment/
_________________________
Theralase Technologies has a 256 per cent upside, says Mackie Research
SEPTEMBER 20, 2019 BY NICK WADDELL
https://www.cantechletter.com/2019/09/theralase-technologies-has-a-256-per-cent-upside-says-mackie-research/
In Sept stock was around .16 - .18 cents.
Currently in January it's at about .25 after an expected pullback from a recent high of .295 in 2020.
______________________
Link to company PRs
https://theralase.com/press-releases/
______________________
Potential upcoming PRs
- announcement(s) of new ph1 trial(s) for new indication(s) (additional cancer types)
- FDA approval of US-based test sites for ph2 NMIBC trials
- additional results from ph 1b trials (over longer time periods)
- JV or other interest from big pharma
- more Canada-based ph2 test sites
- more enrolled patients
Phase 2 study: 6 patients treated.
The company is fully financed to finish StudyII.
As per 1Q2020 Company Quarterly Newsletter.
Phase II NMIBC Clinical Study Status
In 4Q2019, Theralase filed an Investigational New Drug ("IND") application to the Food and Drug Administration ("FDA") for a pivotal Phase II NonMuscle Invasive Bladder Cancer ("NMIBC") clinical study. The IND is currently on Full Clinical Hold pending a response by Theralase, which is expected in 1Q2020.
Pending FDA acceptance of Theralase's response, Theralase will commence onboarding clincial study sites in the United States.
In the mean time, Theralase is proceeding with patient enrollment and study site onboarding in Canada.
University Health Network ("UHN")
The Phase II NMIBC clinical study ("Study II") has successfully launched in Canada, with 3 Canadian centres open for enrollment and treatment of patients.
1.(Toronto, ON) - 5 patients treated
2. McGill University Health Centre ("MUHC")(Montreal, QC) - 1 patient treated
3. London Health Sciences Centre ("LHSC") (London, ON) - 0 patient treated
To date, 6 patients have been treated.
___________________
Financial Highlights:
As per 1Q2020 Company Quarterly Newsletter.
As of November 29, 2019, Theralase has 14.98M in cash and zero debt, except for trade payables. The company is fully financed to finish StudyII.
__________________
Phase 1 (completed study) patients 5 and 6 will be hitting 24 month treatment anniversary's. Both of these patients were cancer free 18 months after single treatment.
If both patients remain cancer free after 24 months from a single treatment, the company will have unprecedented data points.
Phase 1 patients 5 and 6 were respectfully initially treated on Jan 10 and Feb 7, 2018.
https://theralase.com/pressrelease/theralase-anti-cancer-technology-used-to-treat-fifth-patient-for-bladder-cancer/
https://theralase.com/pressrelease/theralase-anti-cancer-technology-treats-sixth-patient-for-bladder-cancer/
https://theralase.com/pressrelease/patient-five-cancer-free-eighteen-months-after-single-anti-cancer-treatment/
https://theralase.com/pressrelease/patient-six-cancer-free-eighteen-months-after-single-anti-cancer-treatment/
_________________________
Theralase Technologies has a 256 per cent upside, says Mackie Research
SEPTEMBER 20, 2019 BY NICK WADDELL
https://www.cantechletter.com/2019/09/theralase-technologies-has-a-256-per-cent-upside-says-mackie-research/
In Sept stock was around .16 - .18 cents.
Currently in January it's at about .25 after an expected pullback.
______________________
Link to company PRs
https://theralase.com/press-releases/
Theralase Technologies has a 256 per cent upside, says Mackie Research
SEPTEMBER 20, 2019 BY NICK WADDELL
https://www.cantechletter.com/2019/09/theralase-technologies-has-a-256-per-cent-upside-says-mackie-research/
In Sept stock was around .16 - .18 cents.
Currently in January it's at about .25 after an expected pullback.
Looking at 3 month chart, pullback was expected.
Phase 1 (completed study) patients 5 and 6 will be hitting 24 month treatment anniversary's. Both of these patients were cancer free 18 months after single treatment.
If both patients remain cancer free after 24 months from a single treatment, the company will have unprecedented data points.
Phase 1 patients 5 and 6 were respectfully initially treated on Jan 10 and Feb 7, 2018.
https://theralase.com/pressrelease/theralase-anti-cancer-technology-used-to-treat-fifth-patient-for-bladder-cancer/
https://theralase.com/pressrelease/theralase-anti-cancer-technology-treats-sixth-patient-for-bladder-cancer/
https://theralase.com/pressrelease/patient-five-cancer-free-eighteen-months-after-single-anti-cancer-treatment/
https://theralase.com/pressrelease/patient-six-cancer-free-eighteen-months-after-single-anti-cancer-treatment/
------------------------
Phase 2 (Active) study:
Operational Highlights: November 29, 2019
Study II progress. Theralase is conducting a Study II with 3 Canadian study sites open for patient enrollment and treatment, specifically, University Health Network (“UHN“), London Health Science Centre (“LHSC“), and McGill University Health Centre (“MUHC“). To date, 4 patients have been treated at UHN and 1 patient treated at MUHC. (20 sites planned with the majority in the US).
https://theralase.com/pressrelease/theralase-releases-third-quarter-2019-financial-results-and-company-update/
-------------------------
Link to company PRs
https://theralase.com/press-releases/
$TLTFF-Theralase Researchers Receive Recognition for Recent Scientific Publications
Toronto, Ontario – November 27, 2019, Theralase® Technologies Inc. (“Theralase” or “Company”) (TSXV: TLT) (OTCQB: TLTFF),
a clinical stage pharmaceutical company focused on the research and development of light activated Photo Dynamic Compounds (“PDC”) and their associated drug formulations intended to safely and effectively destroy various cancers is pleased to announce several scientific recognitions.
The recognition from three scientific institutes emphasizes the strong science-based technology that the Company possesses, verifying that Theralase’s Ruthenium-based PDCs are leading the pack in terms of performance of Photo Dynamic Therapy (“PDT”) metal based PDCs to become the next viable option for treating various cancers, suggesting a major change in the way various cancers are treated in the future.
The review article, titled “Metal-Based photosensitizers for photodynamic therapy – the future of multimodal oncology?”, is available online at www.sciencedirect.com and will be published in a special issue of Current Opinion in Chemical Biology entitled Next Generation Therapeutics, Volume 56, June 2020. The article verifies that the Company’s lead PDC TLD-1433 has strong scientific support, is highly advanced in clinical studies and may become the next “gold standard” cancer treatment.
Gilles Gasser, Ph.D., Principal Investigator, Chimie ParisTech, Université Paris Sciences et Lettres (“PSL”), stated: “In this article, we take the Ruthenium-based agent TLD-1433 developed by Theralase as an example to discuss the use of metal complexes as photosensitizers for PDT. While metal complexes are heavily employed as chemotherapeutics against cancer, their use in PDT is still at its infancy despite their great photophysical properties; however; the entry into Phase II of TLD-1433 against Non Muscle Invasive Bladder Cancer (‘NMIBC”) paves the way for the development of other metal-based photosensitizers.”
Sherri McFarland, Ph.D., Professor, Department of Chemistry University of Texas at Arlington, stated: “It’s an honour to be a part of this special issue on the topic of Next Generation Therapeutics. Theralase’s TLD-1433 has been clinically proven to be a leading PDC in a Phase Ib NMIBC clinical study and may very well lead the way for future clinical investigations using PDT and development of the next generation PDCs.”
On November 15th, Dr. McFarland was an invited lecturer and presented research titled “A ruthenium complex as a photodynamic therapy agent in a phase II clinical trial against cancer” at the Metals in Medicine Workshop, Chimie ParisTech, PSL University. The presentation discussed PDT as an emerging modality in oncology treatments, with the scientific discovery of metal based PDCs and the promising properties of the Ruthenium-based TLD-1433 used in Theralase’s Phase II NMIBC clinical study (“Study II”).
Lothar Lilge, Ph.D., Senior Scientist, University Health Network (“UHN”) and Professor, Medical Biophysics, University of Toronto presented research titled “How to personalize photodynamic therapy treatment: From dose definition to an actual plan” at Chimie ParisTech, PSL University on November 12th. The presentation highlighted the significance of utilizing a chemist, pharmacologist and physicist to work together in order to advance PDT for cancer treatments.
https://theralase.com/pressrelease/theralase-researchers-receive-recognition-for-recent-scientific-publications/
This company is developing a bladder cancer treatment with extremely strong results.
$TLTFF-Anti-Cancer Technology Used to Treat Fifth Patient for Bladder Cancer
Toronto, Ontario – January 18, 2018
Theralase Technologies Inc. (“Theralase®” or the “Company”) (TLT: TSXV) (TLTFF: OTC), a leading biotech company focused on the commercialization of medical devices to eliminate pain and when used in conjunction with Photo Dynamic Compounds (“PDCs”) to destroy cancer, announced today that the fifth patient in a Phase Ib Non-Muscle Invasive Bladder (“NMIBC”) clinical study (“Study”) was enrolled and treated on January 10, 2018, using the Company’s anti-cancer Photo Dynamic Therapy (“PDT”) technology.
Theralase® Anti-Cancer Technology Used to Treat Fifth Patient for Bladder Cancer
Toronto, Ontario – January 18, 2018
Theralase Technologies Inc. (“Theralase®” or the “Company”) (TLT: TSXV) (TLTFF: OTC), a leading biotech company focused on the commercialization of medical devices to eliminate pain and when used in conjunction with Photo Dynamic Compounds (“PDCs”) to destroy cancer, announced today that the fifth patient in a Phase Ib Non-Muscle Invasive Bladder (“NMIBC”) clinical study (“Study”) was enrolled and treated on January 10, 2018, using the Company’s anti-cancer Photo Dynamic Therapy (“PDT”) technology.
Uptrend low channel line supports .05 buying.